TRT and the Prostate: Does Testosterone Increase Prostate Cancer Risk?

If you've ever talked to an older-generation doctor about testosterone therapy, you probably heard some version of: 'testosterone feeds prostate cancer, so it's better not to risk it.' That's not a random opinion — it's an echo of one of the most influential discoveries in the history of oncology, one that was interpreted more broadly for decades than the data actually supported. Understanding where this rule came from is the key to understanding why it's now largely regarded as an overextension — though not in every clinical situation.

The story begins in 1941, when Charles Huggins and Clarence Hodges published a paper showing that surgical or pharmacological castration — a drastic reduction in androgen levels — led to a visible shrinking of prostate cancer metastases. It was a therapeutic breakthrough of the first order: for the first time, a solid tumor had been shown treatable through hormonal manipulation rather than surgery or radiation alone. Huggins received the Nobel Prize in Physiology or Medicine in 1966 for this work, and androgen deprivation therapy (ADT) remains a cornerstone of advanced prostate cancer treatment to this day.

Huggins and Hodges' work concerned men with already-diagnosed, advanced prostate cancer — and showed that removing androgens slows a disease that already exists. Over the following decades, this observation was generalized into a much broader, intuitively appealing rule: if a lack of testosterone slows cancer, then more testosterone must fuel it, and any rise in the hormone's level — including from replacement therapy in a healthy man — should increase the risk of developing the disease, or of speeding the growth of an as-yet-undetected tumor.

For most of the 20th century, this extrapolation seemed logical enough that it was rarely challenged outright. As a result, any elevated testosterone level — whether natural or therapy-induced — was treated as a potential oncological threat, and for decades doctors withheld TRT even from men with a clear, confirmed deficiency, purely because they had a prostate. The problem was that no one had systematically checked whether raising testosterone in men WITHOUT prostate cancer actually increases the risk of developing it — the assumption functioned as clinical dogma before anyone properly tested it.

A breakthrough in understanding this relationship came from a concept developed by American urologist Abraham Morgentaler, known as the saturation model. Its central claim: androgen receptors in prostate tissue have a limited capacity to bind testosterone, and at relatively low hormone concentrations they become saturated. In other words — prostate cells need a certain minimum amount of testosterone for the androgen receptors to start responding, but once that threshold is crossed, further increases in blood hormone concentration no longer translate into proportionally stronger stimulation of tissue growth.

Notably, Morgentaler himself presented the saturation model from the start as an explanatory hypothesis — consistent with available clinical data, but not proven down to every molecular detail. The scientific community received it with cautious enthusiasm: some researchers in subsequent years questioned the exact value of the saturation threshold and whether the model explains every observed phenomenon, while the clinical observation itself — that TRT in men without prostate cancer doesn't, in practice, increase the risk of developing it — has since been repeatedly confirmed independently of whether we accept the saturation model as a fully accurate explanation of the mechanism.

A mechanistic theory is one thing, but in medicine, what matters most is what the data from real patients show. Over the past two decades, many randomized clinical trials and observational studies have assessed the effect of testosterone therapy on prostate cancer risk — and none of the large, well-designed studies have shown a statistically significant rise in risk in men without a prior cancer diagnosis.

This meta-analysis's result is representative of the whole direction the literature has taken over the last twenty years — subsequent systematic reviews, including analyses covering dozens of randomized trials and cohorts numbering tens of thousands of patients, repeat the same pattern: no convincing signal that TRT used according to indications increases the risk of developing prostate cancer in men who didn't previously have it. That doesn't mean the topic is fully settled — most studies have a limited follow-up period (usually a few years, less often over a decade), and prostate cancer can be a disease with a slow, multi-year course, so long-term data remain valuable and worth pursuing. But the direction of the evidence today is clear and consistent.

This is where honesty requires visibly dialing back the enthusiasm. Everything written above concerns men WITHOUT diagnosed prostate cancer — for them, the evidence for TRT's safety is today relatively solid. A completely different, much more complex clinical category are men who have had or currently have prostate cancer. Different rules apply here, and decisions require far more caution.

The picture looks different for men whose prostate cancer was previously definitively treated — surgically (radical prostatectomy) or with radiotherapy — and who, after completing treatment, developed symptomatic testosterone deficiency, which is itself a common side effect of the cancer treatment. For decades such a history automatically excluded TRT, regardless of how long ago and how successfully the cancer had been treated. In recent years this approach has started to shift, as observational data emerge suggesting that in carefully selected patients — with low recurrence risk, after an appropriate observation period, and under strict monitoring — TRT may be considered.

This is important, reassuring data — but it needs to be read with appropriate methodological caution. This was an observational, not randomized, study, meaning patients whom doctors chose to qualify for TRT likely already had a more favorable baseline risk profile (lower disease stage, more time since treatment, no signs of aggressive disease) than those who weren't offered it — this kind of selection may have partly flattened the real differences in outcomes. Despite this limitation, data of this kind from large cohorts, replicated across several independent observational studies, are gradually shifting the urology community's approach to this group of patients — from a hard, universal ban toward an individualized assessment of risks and benefits.

A shift in understanding oncological risk doesn't mean abandoning vigilance. Even in men without a history of prostate cancer starting TRT for a confirmed deficiency, regular PSA monitoring remains the standard of care — before starting therapy, a few months after starting or changing dose, and then cyclically for the entire duration of treatment. This isn't a relic of old fears about testosterone, but sound clinical practice: PSA remains the best widely available, if imperfect, tool for early detection of prostate problems in the general population, regardless of whether a given man is on TRT or not.

It's also worth remembering that PSA as a test has its own well-documented limitations — low specificity and a significant rate of false positives, more often caused by benign prostatic enlargement than by cancer. We cover this more extensively in a separate article on PSA and prostate health — a natural companion piece if you want to understand how to interpret a specific result.

If you were to take away one sentence from this article, let it be this: the old fear of testosterone as a universal 'fuel' for prostate cancer was an overextension of one, otherwise valid, discovery from more than 80 years ago — not an independently proven rule. In men without a prior prostate cancer diagnosis who qualify for TRT under clinical guidelines, the evidence available today — mechanistic models, randomized trials, and meta-analyses — consistently shows no increased risk of developing the disease.

At the same time, this same body of evidence gives no grounds for dismissing the topic in men who have had, or have, prostate cancer. There, TRT decisions — if considered at all — should always go through a urologist or oncologist who knows the patient's full disease history, never through a self-directed interpretation of general statistics from an article online. The good news from recent years is that even in this more cautious group, data are emerging to suggest that a hard, universal ban is giving way to a more nuanced, individualized approach — but this remains a topic requiring specialist care, not a self-made decision.